Improved scores in
reported in as soon
as 15 minutes
In a clinical study, KYNMOBI improved motor symptoms when taken during an OFF episode
In the KYNMOBI clinical study, people with Parkinson's disease (PD) and taking carbidopa/levodopa were assigned to also take either KYNMOBI or a placebo to treat their OFF episodes.
The main objective of the KYNMOBI clinical study was to improve motor symptoms at 30 minutes as defined by the Movement Disorder Society‐Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III. In the study, 54 patients received KYNMOBI and 55 patients received placebo.
Other goals of this study measured movement symptoms using the same scale at different times (eg, at 15 minutes and 90 minutes) after taking KYNMOBI during an OFF time. These results are observational and descriptive in nature.
KYNMOBI may help you get to your Full ON during an OFF episode
as many people on KYNMOBI
reported achieving a Full ON
compared to placebo
(35% vs 16%)*
*The key secondary objective of the
KYNMOBI clinical study was the percentage
of people who reported a Full ON response within 30 minutes.
In the KYNMOBI clinical study, Full ON was defined as a time when people experienced at least one of the following†:
†Patients assessed a Full ON using these 3 components, which were not individually recorded.
The most common side effects in the KYNMOBI 12-week clinical study were:
- Mouth swelling, pain, or sores
KYNMOBI can cause serious side effects, including:
- Sleepiness or falling asleep during the day
- Mouth (oral) irritation
- Hallucinations or psychotic-like behavior
- Strong (intense) urges
- High fever and confusion
- Heart problems
- Tissue changes (fibrotic complications)
- Prolonged painful erections (priapism)
Hear John describe his experience after starting KYNMOBI